PCH: Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System

Product code PCH, “Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System” in FDA's classification database, is a Class II device type under 21 CFR 866.3990 (gastrointestinal microorganism multiplex nucleic acid-based assay), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 38 clearances under PCH, 38 of them since 2011.
Updated Oct 29, 2026 · Clearances from FDA’s 510(k) database, as of Oct 29, 2026
Product code
PCH
Regulation
21 CFR 866.3990
Class
II
Panel
Microbiology
Clearances
38
Most recent
May 19, 2026
Median review, last 2 years
90 days
Third-party review
Not eligible
Implant
No

What it covers

A gastrointestinal pathogen panel multiplex nucleic acid assay is a qualitative in vitro diagnostic device intended to simultaneously detect and identify multiple gastrointestinal microbial nucleic acids extracted from human stool specimens. The detection and identification of a specific gastrointestinal microbial nucleic acid from individuals exhibiting signs and/or symptoms of gastrointestinal infection aids in the diagnosis of gastrointestinal infection when used in conjunction with clinical evaluation and other laboratory findings.

FDA’s definition of product code PCH, from the Product Classification database.

Recent clearances

510(k)DeviceApplicantDecisionType
K253722LIAISON PLEX Gastrointestinal Flex AssayLuminex CorporationMay 19, 2026Traditional
K254032QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini BQIAGEN GmbHMar 9, 2026Traditional
K251721Xpert GI PanelCepheidJan 16, 2026Traditional
K252329QIAstat-Dx Gastrointestinal Panel 2; QIAstat-Dx GI Panel 2 Mini B&V; QIAstat-Dx GI Panel 2 Mini BQIAGEN GmbHOct 22, 2025Traditional
K251993Panther Fusion GI Expanded Bacterial AssayHologic, Inc.Sep 25, 2025Traditional
K251868Panther Fusion GI Bacterial AssayHologicSep 25, 2025Traditional
K250324QIAstat-Dx GI Panel 2 Mini BQIAGEN GmbHFeb 28, 2025Special
K243885BIOFIRE FILMARRAY Gastrointestinal (GI) Panel MidBiofire Diagnostics, LLCJan 16, 2025Special
K242877BioCode Gastrointestinal Pathogen Panel (GPP)Applied BioCode, Inc.Jan 10, 2025Traditional
K243813QIAstat-Dx GI Panel 2 Mini B&VQIAGEN GmbHJan 8, 2025Special
From FDA’s 510(k) database, as of Oct 29, 2026Export CSV (100 rows free · all 38 with a free account)

Clearances by year

38 PCH 510(k)s were cleared from 2011 to Oct 29, 2026. Days to decision run from the day FDA received the 510(k) to its decision, including time on hold.

YearClearancesMedian days to decision
2026 (so far)3176
2025789
20243271
2023129
20222205
20194191
20184105
2017190
20162105
20152184
20146120
2013389

Who submits

16 applicants cleared a PCH device since 2011. 61% of the clearances went to applicants in United States, then Canada (21%), Germany (13%) and Australia (3%). By type: Traditional 74%, Special 24% and Post-NSE 3%.

ApplicantClearances since 2011
Luminex Molecular Diagnostics, Inc.8
Becton, Dickinson and Company5
Biofire Diagnostics, LLC5
QIAGEN GmbH5
Applied BioCode, Inc.3
Cepheid2
Biofire Diagnostics1
Gen-Probe Prodesse, Inc.1

How FDA classifies it

Class II (special controls). The special controls are set forth in FDA's guideline document entitled: “Class II Special Controls Guideline: Gastrointestinal Microorganism Multiplex Nucleic Acid-Based Assays for Detection and Identification of Microorganisms and Toxin Genes from Human Stool Specimens.” For availability of the guideline document, see § 866.1(e).

From 21 CFR 866.3990. Special controls are the requirements a 510(k) must show it meets.

Standards

21 CFR 866.3990 names no consensus standards. Check FDA’s recognized standards database, or ask which standards recent PCH clearances declared.

Ask about PCH

US FDA devices: 510(k), De Novo, guidance, 21 CFR

Questions about PCH

What is FDA product code PCH?

Product code PCH, “Gastrointestinal Pathogen Panel Multiplex Nucleic Acid-Based Assay System” in FDA's classification database, is a Class II device type under 21 CFR 866.3990 (gastrointestinal microorganism multiplex nucleic acid-based assay), reviewed by FDA's Microbiology panel. FDA's 510(k) database lists 38 clearances under PCH, 38 of them since 2011.

How many 510(k) clearances are there under PCH?

FDA’s 510(k) database listed 38 clearances under PCH as of Oct 29, 2026, 38 of them decided since 2011; the most recent decision was May 19, 2026. The Predicate Finder searches the live database.

How long does FDA take to clear a PCH 510(k)?

For the 11 PCH clearances decided in the two years before Oct 29, 2026, the median time from FDA receiving the 510(k) to its decision was 90 days. That counts calendar days, including time the submission was on hold waiting for answers from the submitter.

Which companies have the most PCH clearances?

Since 2011: Luminex Molecular Diagnostics, Inc. (8), Becton, Dickinson and Company (5), Biofire Diagnostics, LLC (5), QIAGEN GmbH (5) and Applied BioCode, Inc. (3). 16 applicants have cleared a PCH device in that time.

Sources

  1. FDA product classification: PCH · Product Classification database
  2. 21 CFR 866.3990: Gastrointestinal microorganism multiplex nucleic acid-based assay · eCFR, as of Oct 27, 2026
  3. openFDA 510(k) query for PCH · run Oct 29, 2026
  4. 510(k) Premarket Notification database · FDA, accessdata.fda.gov
Follow PCHGet an email when FDA clears, recalls or publishes guidance for PCH devices.

Know what FDA already cleared.